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Aims The clinical application of doxorubicin (DOX) is severely compromised by its cardiotoxic effects, which limit the
therapeutic index and the cumulative dose. Liposomal encapsulation of DOX (MyocetVR ) provides a certain protec-
tive effect against cardiotoxicity by reducing myocardial drug accumulation. We aimed to evaluate transcriptomic
responses to anthracyclines with different cardiotoxicity profiles in a translational large animal model for identifying
potential alleviation strategies.
....................................................................................................................................................................................................
Methods
and results
We treated domestic pigs with either DOX, epirubicin (EPI), or liposomal DOX and compared the cardiac, labora-
tory, and haemodynamic effects with saline-treated animals. Cardiotoxicity was encountered in all groups, reflected
by an increase of plasma markers N-terminal pro-brain-natriuretic peptide and Troponin I and an impact on body
weight. High morbidity of EPI-treated animals impeded further evaluation. Cardiac magnetic resonance imaging with
gadolinium late enhancement and transthoracic echocardiography showed stronger reduction of the left and right
ventricular systolic function and stronger myocardial fibrosis in DOX-treated animals than in those treated with the
liposomal formulation. Gene expression profiles of the left and right ventricles were analysed by RNA-sequencing
and validated by qPCR. Interferon-stimulated genes (ISGs), linked to DNA damage repair and cell survival, were
downregulated by DOX, but upregulated by liposomal DOX in both the left and right ventricle. The expression of
cardioprotective translocator protein (TSPO) was inhibited by DOX, but not its liposomal formulation. Cardiac fi-
brosis with activation of collagen was found in all treatment groups.
....................................................................................................................................................................................................
Conclusions All anthracycline-derivatives resulted in transcriptional activation of collagen synthesis and processing. Liposomal
packaging of DOX-induced ISGs in association with lower cardiotoxicity, which is of high clinical importance in anti-
cancer treatment. Our study identified potential mechanisms for rational development of strategies to mitigate
anthracycline-induced cardiomyopathy.
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Graphical Abstract
1. Introduction
The 5- to 10-year survival rates of patients suffering from certain
tumours, such as breast, haematologic, or childhood cancers exceed
80%. This is mainly due to refined therapy by chemotherapeutics, such as
anthracyclines, immunotherapies, other specific treatments, and/or tar-
geted tumour excision or irradiation.1 Unfortunately, 10–75% of cancer
survivors suffer from chronic health issues in later life, including heart fail-
ure, vascular or valve diseases, and other cardiac complications, caused
by toxicity of many chemotherapeutics.2 Anthracyclines are one of the
most frequently used anticancer drugs. Recent data of a study in adult
cancer patients showed that the majority of cardiovascular toxicity, de-
fined as a decrease of left ventricular (LV) ejection fraction (EF),
occurred within the first year after the completion of doxorubicin
(DOX) chemotherapy.3 The development of cardiotoxicity correlates
with the cumulative anthracycline dose. Clinical studies and the ESC
guidelines suggest that early detection and eventual treatment of heart
failure of patients exposed to anticancer agents might allow for a partial
or complete recovery of LV dysfunction and positively impacts cardiac
outcome.4,5 The treatment usually includes an angiotensin-converting
enzyme-inhibitor and further adjuvant therapies against heart insuffi-
ciency. An inverse relationship has been found between the time to car-
diac treatment and clinical outcome in cancer patients.4
Current means to mitigate anthracycline-induced cardiotoxicity are
limited.5 On the molecular level, the cytostatic effect of anthracyclines is
attributed to DNA intercalation, DNA binding and cross-linking,
2 M. Gyo¨ngyo¨si et al.
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inhibition of topoisomerase II, and induction of apoptosis.
Cardiomyocyte damage is caused by oxidative stress, generation of reac-
tive oxygen species (ROS), inhibition of nucleic acid synthesis, and de-
creased expression of contractile proteins.6 In small animal models,
cardiotoxicity was mediated by topoisomerase-IIb (Top2b).7
Cardiomyocyte-specific depletion of Top2b protected mice from DOX-
induced heart failure. In pigs, transcriptional activation of several matrix
metalloproteinases was found after DOX administration.8 It has been
shown that DOX triggers several signalling pathways, such as the MAPK,
p53, Jak-STAT, Wnt, MAPK/p53, or PPAR pathways, which might all be
involved in DOX-associated cardiomyopathy.9,10 Proposed strategies
for mitigation of cardiotoxicity include iron chelation,11 VEGF-B gene
therapy,12 stimulation of oxidative phosphorylation,9 modulation of
DNA damage and oxidative stress,10 or targeting an RNA-binding pro-
tein.13 However, a comprehensive high throughput transcriptomic
screening of genes or proteins in a translational large animal model of
cardiotoxicity had not yet been performed.
In relation to their therapeutic dose, the cardiotoxicity risks and anti-
cancer outcomes of DOX and its stereoisomer epirubicin (EPI) are simi-
lar, because epimerization reduces not only toxicity, but also therapeutic
effects.14 The use of liposomal DOX formulations has reduced cardio-
toxicity because of lower myocardial drug concentrations.14 Liposomes
are designed to avoid direct contact of the cytotoxic agent with the vas-
culature, and influence biodistribution based on leakiness of the endo-
thelium of various organs.15 Both unPEGylated (MyocetVR /MYO) and
PEGylated liposomal formulations of DOX (CaelyxVR /DoxilVR ) are in clini-
cal use.
The aim of our study was to investigate molecular mechanisms and
impact on gene expression profile of DOX, the liposomal formulation of
DOX, MyocetVR (MYO), and EPI in a large animal model, to facilitate
pharmacological research for cardioprotection during anticancer treat-
ment. Pigs are excellent translational models for investigating cardiac ad-
verse events. The cardiovascular anatomy, physiology, and pathology of
pigs compares favourably to that of humans, with the possibility of car-
diac imaging with human clinical cameras. Instead of investigation of a pri-
ori selected transcripts or proteins, we aimed to perform an unbiased
approach of global transcriptomic profiling for comprehensive insight
into signal transduction pathways and for discovering multiple potential
molecular targets16 and confirmed our findings in in vitro cell culture
experiments.
2. Methods
2.1 Animal study design
The investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health
(NIH Publication No. 85-23, revised 1985). Animal experiments were
performed at the Institute of Diagnostic Imaging and Radiation
Oncology, University of Kaposvar, Hungary and were approved by the
ethics committee (EK: 1/2013-KEATK DOI, MUW §27 Project
FA714B0518).
Twenty-three domestic pigs (Sus scrofa, female large whites 30± 2 kg,
3 months old) were randomized into four groups receiving either DOX
(group DOX, n¼ 6), EPI (group EPI, n¼ 6), Myocet (group MYO, n¼ 6),
or physiologic saline (group CO, n¼ 5) in doses equivalent to human
treatment regimens (60 mg/m2 body surface area DOX and MYO,
100 mg/m2 EPI) as a single 1-h intravenous infusion every 21 days (at
Days 1, 22, and 43). Liposomal DOX was prepared directly before the
injection according to the manufacturer’s instructions. DOX and EPI
were dissolved in saline solutions. Pigs were sedated with 12 mg/kg keta-
mine hydrochloride, 1.0 mg/kg xylazine, and 0.04 mg/kg atropine. An in-
travenous infusion of the drug or saline was administered via puncture of
the femoral vein. Instead of the human equivalent of six treatment cycles,
the experiment was terminated early after concluding three cycles, due
to the bad health conditions of the surviving animals. After animal inspec-
tion, higher mortality was assumed by continuing the treatment, there-
fore cardiac MRI was performed followed by sacrification of the animals
at Day 60. All available samples were included in the respective analyses.
Transthoracic echocardiography (TTE) was performed after each in-
jection to evaluate the systolic and diastolic functions. Blood samples
were collected at baseline, after the 1st and before the 2nd and 3rd
treatments, and before termination. Before the 1st treatment (Day 1),
and 2 weeks after the 3rd infusion (Day 58 ± 1), cardiac magnetic reso-
nance imaging (cMRI) with late enhancement (LE) was performed to as-
sess the right ventricular (RV) and LV systolic cardiac function and
fibrosis. For euthanasia, during continuous deep anaesthesia (1.5–
2.5 vol% isofluran, 1.6–1.8 vol% O2, and 0.5 vol% N2O), an additional
dose of intravenous heparin (10 000 U) and 10 mL intravenous saturated
potassium chloride (10%) were administered. Hearts were explanted
and samples from the left and right ventricles were excised.
2.2 Blood biomarkers
Blood cell counts (numbers of red and white blood cells/RBC, WBC/,
platelets) and haemoglobin values were quantified by using Siemens
ADVIA 120 equipment. The normal ranges for pigs are 6.0-9.0 106/mL
for RBC, 10-23 103/mL for WBC, 150-450 x103/mL for platelets and 110-
170 g/L for haemoglobin. Serum creatinine (normal range 20-200mM/L)
and aspartate-aminotransferase (AST, normal range 10-45 U/L) were
measured by routine clinical chemical tests. Plasma troponin I (normal
value in pigs <0.15 ng/mL), N-terminal pro-brain-natriuretic peptide
(NT-proBNP, normal value <136 pg/mL) and creatine kinase (CK, nor-
mal range 0–100 U/L) were determined using porcine troponin I type 3,
cardiac (CTNI) ELISA (MyBioSource, San Diego, CA, USA), porcine NT-
ProBNP ELISA (MyBioSource, San Diego, CA, USA), and porcine crea-
tine kinase ELISA Kits (Abcam, Cambridge, UK).
2.3 cMRI image acquisition and volumetric
MRI measurements
We performed cMRI on a 1.5 T Siemens Avanto Syngo B17 scanner
(Erlangen, Germany) with a phased-array coil and a vector ECG system.
Functional scans were acquired using a retrospective ECG-gated (HR:
80-100 beats/minute), steady-state free precession (SSFP - TRUFISP se-
quence) technique in short-axis and long-axis views using 1.2 ms echo
time (TE), 40 ms repetition time (TR), 25 phases, 50 flip angle, 360 mm
field-of-view, 8 mm slice thickness, and 256 x 256 image matrix. For
quantitative evaluation of myocardial fibrosis, LE diastolic phase images
were obtained after injection of 0.05 mmol/kg contrast medium using an
inversion recovery prepared, gradient-echo MRI sequence. Short-axis
and long-axis images were obtained 10-15 minutes after gadolinium
injection.
Volumetric MRI measurements and visualizations were performed us-
ing the software Segment version 1.9 (Medviso AB, Lund, Sweden).17
We performed semi-automatic segmentation of the LV endocardial and
epicardial borders, extending from the most basal short-axis view slice in
which the myocardium could be seen in 360 degrees to the most apical
slice. Using 3 D volumetry, end-diastolic (EDV), end-systolic volumes
Interferon response in anthracycline cardiotoxicity 3
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(ESV), global LV EF were automatically calculated on short-axis cine MRI
images. EDV and ESV were related to the body weight (EDVi and ESVi).
2.4 Transthoracic echocardiography
Routine TTE was performed at baseline, and during anaesthesia for each
infusion treatment. We measured the diameter of the left ventricle from
the M-mode of the long-axis parasternal view to assess the global LV sys-
tolic function. Pulsed wave Dopplers of diastolic function were recorded
by measurements of mitral E and A waves and the E/e0 ratio by using 4-
chamber view. RV systolic function was assessed by measurement of tri-
cuspid annular plane systolic excursion (TAPSE).
2.5 Histology and immunohistochemistry
LV and RV myocardial samples were stored in formalin, or RNAlater, or
fresh frozen. Myocardial samples were stained for fibrosis, ki67, and cas-
pase activity (Supplementary material online).
2.6 Western blot
To assess cleaved (active) caspase 3 activity in the LV of DOX and MYO
animals, a quantitative western blot was performed, of 5 DOX and 6
MYO LV samples, in duplicate. Forty micrograms of protein was loaded
into each well of a NuPAGETM 10% Bis-Tris gel. After electrophoresis,
the proteins were transferred onto an Immun-BlotVR PVDF Membrane
(0.45mm pore size, BioRad). The membrane was cut in half at the 40 kDa
marker to stain cleaved caspase 3 (17 kDa) and beta tubulin (50 kDa)
separately. The membranes were stained using cleaved caspase 3 Ab
(ab13847, Abcam) and beta Tubulin Ab (NB600-936, Novus Biologicals)
as loading control. Densitometric analysis was carried out using ImageJ
(Rasband, W.S., ImageJ, U.S. National Institutes of Health, Bethesda, MD,
USA) by measuring the area under the curve (AUC) of a histogram of
each lane in the western blot. The AUC values for caspase 3 were di-
vided by the value of the corresponding loading control to normalize for
protein loading.
2.7 Transcriptomic profiling
Detailed methods are described in the Supplementary material online.
Briefly, after RNA isolation and enrichment of coding genes by poly(A)
selection, libraries were prepared and analysed on an Illumina NGS sys-
tem with paired-end sequencing. Results were mapped to the pig tran-
scriptome and analysed for statistically significant changes of individual
genes and pathways. For investigation of biological relevance, groups
were compared and significantly deregulated genes were functionally
clustered.
2.8 DOX effects on isolated human
cardiomyocytes
Human cardiac myocytes isolated from adult left ventricles (PromoCell,
Heidelberg, Germany) were cultured according to the manufacturer’s
instructions. For gene expression analyses, cells were treated with DOX
(6.25 and 1.56 nM) in 48 well plates (2  104 cells per well) for 48 h,
lysed in Qiazol (Qiagen). RNA was isolated with an RNeasy micro kit fol-
lowed by cDNA synthesis with a QuantiTect RT kit and qPCR with Sybr
Green (all Qiagen) according to the manufacturer’s instructions. For cy-
totoxicity testing, cells were seeded into 96 well plates (104 cells per
well) and incubated for 24 h in standard cell culture medium. For induc-
tion of interferon-inducible genes, poly (I:C) was applied in a concentra-
tion of 1mg/mL, and cells were further incubated for 4 h. DOX was
added to pretreated and control cells in concentrations of 10mM, 1mM,
400 nM, 100 nM, 25 nM, 6.25 nM and 0.1 nM, and cells were incubated
for 48 h. Cytotoxicity was assessed with an EZ4U cell proliferation and
cytotoxicity kit (Biomedica, Vienna, Austria), based on the derivatization
to a formazan dye, according to the manufacturer’s instructions, and ab-
sorption was read after 4 h. A second cytotoxicity assay was performed
for direct comparison of the effect of DOX and Myocet on cell viability,
using the same methods and dosages as described above without poly
(I:C) stimulation.
2.9 Statistics
Differences between treatment and control groups were tested for nor-
mality with Shapiro–Wilk, and parametric data were evaluated for statis-
tical significance using one-way ANOVA tests with Bonferroni post hoc
corrections. The Kaplan–Meier survival analysis was calculated for all
groups. A difference was considered statistically significant at P< 0.05.
Data analyses and interpretations were performed by an experienced
observer who was blinded to the randomization and to results.
Statistical analysis was performed using SPSS 18.0 (SPSS Inc., USA) soft-
ware, and graphs were prepared in SigmaPlot 13.0 (Systat Software Inc.,
USA). Sample sizes for all figures are n¼ 6 for DOX and MYO, and
n¼ 5 for controls, unless otherwise indicated.
For gene array analysis, to test for all comparisons (i.e. differences be-
tween regions of interest: LV and RV in DOX vs. CO and MYO vs. CO)
a linear model for each gene was fitted and the estimated coefficients
and standard errors for these contrasts were computed.
3. Results
3.1 Study design and survival
Animals of the DOX and MYO groups showed better survival (Figure
1A) compared to group EPI. The two surviving EPI animals had obvious
symptoms of cardiotoxicity (highly elevated troponin I and NT-proBNP
with low LV EF). Due to the insufficient number of surviving animals, the
EPI group was excluded from the further analyses. The reasons of pre-
mature death were leucopenia and thrombocytopenia (one DOX and
two EPI pigs), renal failure (one EPI and one MYO pig), and haemorrhagic
perimyocarditis in one EPI animal. Obduction revealed haemorrhagy in
the right ventricle and haemorrhagic pericarditis in one DOX and one
EPI pig, and pericarditis (two) and haemorrhagic pericarditis (one) in
three EPI pigs. All deceased animals in the cytostatic treatment groups
had elevated Troponin I and NT-proBNP levels.
3.2 Body weight, biomarkers, and
myocardial fibrosis
The weight of the MYO and control pigs was significantly higher after the
first treatment until the end of the experiments compared to the pigs in
the DOX group, indicating better general health of these animals (Figure
1B). Both NT-proBNP and TnI increased during cytostatic treatment
and was in pathologic range in all animals of both groups (Figure 1C, D).
The baseline values of the RBC, WBC, platelet, haemoglobin, AST, and
creatinine did not differ between the groups (Supplementary material
online, Figure S1). A significant drop of the number of platelets was mea-
sured in both DOX and MYO groups, while the liver and kidney function
parameters increased significantly in both groups.
Blood cell counts showed a mild decrease of red blood cells and plate-
lets before the 3rd and 2nd treatment cycle, respectively. Mild but signifi-
cant elevation of creatine kinase (CK) was detected in DOX pigs after
4 M. Gyo¨ngyo¨si et al.
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absent after the 3rd treatment, showing the insensitiveness of CK as a
cardiotoxicity biomarker (Supplementary material online, Figure S1).
Aspartate aminotransferase as a marker for hepatotoxicity also showed
a slight increase starting after the first treatment but not during further
treatment cycles.
HE and MOVAT staining of the LV and RV samples showed disorien-
tation of muscle fibres in hearts in all three treatment groups
(Supplementary material online, Figure S2). Picrosirius red staining
revealed smaller degrees of LV (6.8± 2.1% vs. 8.6± 1.4% vs. 11.0± 2.0%)
and RV (6.5± 1.7% vs. 8.7± 1.0% vs. 9.1 ± 1.0%) fibrosis of the MYO pigs
as compared to the DOX and EPI animals (n¼ 6, P< 0.05 MYO vs.
Figure 1 Clinical data of animals treated with doxorubicin (DOX), MyocetVR (MYO), or epirubicin (EPI) in comparison to animals treated with physiologic
saline infusions (CO). (A) Survival: due to low survival rates of epirubicin-treated pigs, they were excluded from further analyses. (B–D) Body weight and car-
diac markers. The weights of the MYO pigs were significantly higher than those of DOX pigs after the first treatment until the end of the experiments indi-
cating better general health (B). Levels of TnI (C) and NT-proBNP (D) increased during the experiment and were in the pathologic range in all DOX and
MYO animals. *P< 0.05 CO vs. MYO/DOX, #P< 0.05 DOX vs. CO/MYO (ANOVA with Bonferroni post hoc test).
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..DOX). Overall, the assessment of cardiac function and histology show
that MYO-treated animal developed less severe cardiotoxicity than
DOX-treated pigs, although the markers TnI and NT-proBNP were in-
creased in a similar extent.
Supplementary material online, Figure S2 shows representative histo-
logical images of the LV and RV in DOX, MYO, and EPI groups with myo-
cardial tissue fibrosis.
3.3 Systolic and diastolic cardiac function
Baseline LV and RV function was normal in all animals (mean LV EF
62.6± 6.2%, LV EDV 62 ± 9 mL, ESV 38± 8 mL). Two weeks after the
3rd treatment, cMRIþLE showed that animals in the MYO group had
higher RV EF (P< 0.05) than those in the DOX group, and we found a
trend towards higher LV EF, smaller LV and RV end-diastolic volume in-
dex (EDVi) and end-systolic volume index (ESVi) (Figure 2D) in the MYO
pigs. TTE showed impaired LV diastolic function in DOX, but not MYO
animals, and RV systolic dysfunction (Figure 3).
3.4 Transcriptomic profiling
PCA, illustrating similarities and variations of complex datasets, shows
strongly altered gene expression profiles in LV and RV of DOX and
MYO groups compared to CO (Supplementary material online, Figure
Figure 2 Cardiac fibrosis of pigs treated with doxorubicin (DOX), Myocet (MYO), or physiologic saline (CO). (A and B) Cardiac magnetic resonance im-
aging (cMRI) with late enhancement, short-axis view. Animals in both groups showed distinct fibrosis in the right and left ventricle (red arrows). (C)
Representative short-axis images of the RV and LV of DOX (upper panel) and MYO (bottom panel) animals. Better contraction capacity of animals in
Group MYO (bottom panel) as compared with Group DOX (upper panel) with end-diastolic (left) and end-systolic (right) contours of the LV. (D) Cardiac
function of the pigs related to body weight, assessed by cMRI. LV and RV index (EDVi, end-diastolic volume; ESVi, end-systolic volume, both related to body
weight, n¼ 5 for all groups), and function (EF, ejection fraction; n¼ 4 for Control LV and DOX RV, n¼ 5 for others). Group MYO animals presented similar
LV and RV function as the Group CO animals. #P< 0.05 DOX vs. CO, *P< 0.05 DOX vs. MYO (ANOVA with Bonferroni post hoc test).
6 M. Gyo¨ngyo¨si et al.
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..S3). RV gene expressions of the MYO pigs were slightly closer to con-
trols, while moderate differences between DOX and MYO pigs were
identified. Venn diagrams (Supplementary material online, Figure S4) re-
veal considerable overlap (i.e. genes up- or downregulated in both DOX
and MYO groups), but also differences in response to either treatment.
3.5 Cardioprotective mechanisms of
liposomal DOX
For assessing the mechanistic differences between cardiotoxicity caused
by liposomal and free DOX, we compared the respective gene signa-
tures. Functional clusters of dysregulated genes include apoptosis regula-
tion, proto-oncogenes and oncogenes, cellular homeostasis and DNA
repair, collagen synthesis, metabolism, and cytoskeleton (Figure 4 and
Supplementary material online, Table S1). Additional genes with signifi-
cant alterations, which could not be allocated to these clusters, are listed
in Supplementary material online, Table S2.
A direct comparison of gene clusters (Figure 5 and Supplementary ma-
terial online, Table S3) shows consistently stronger expression of
interferon-responsive genes after MYO treatment. In relation to
controls, most of these genes are downregulated by DOX, but upregu-
lated by MYO (Supplementary material online, Figures S5 and S6).
Interferon-stimulated genes (ISGs) are induced upon certain degrees of
DNA damage and can mediate pro-survival signals.18 Among those
genes, we found altered expression between DOX and MYO of IFIT1
and 2, ISG15, OAS2, and Poly(ADP-ribose)-polymerases (PARP) 1, 9,
and 14. PARP 1 and other family members are important mediators of
DNA repair, and link cytostatic damage to autophagy and survival mech-
anisms.19 Interferon and ISGs are biomarkers for immune response and
cell survival after DNA damage, and the gene signature reported here
appears to be instrumental in the attenuation of cardiotoxicity by
Myocet.20
Genes mediating direct responses to cell stress (heat shock proteins
and transcription factors) were generally upregulated after DOX and
downregulated after MYO treatment (Figure 4). Several genes of the
HSP70 family exhibited this differential expression while other HSPs, in-
cluding HSPA4, HSPA5, HSPB1, and HSPD1, showed stronger upregula-
tion in the DOX than in the MYO group. Heat shock protein 47/
SERPINH1 is a molecular chaperone for collagen, providing a link to
Figure 3 Echocardiographic parameters of the pigs treated with doxorubicin (DOX), Myocet (MYO), or physiologic saline (CO). (A) M-mode echocardi-
ography of the left ventricle of CO (left), MYO (mid), and DOX (right) animals. (B) Pulsatile Doppler of the mitral valve, for calculation of E/A ratio of CO
(left), MYO (mid), and DOX (right) animals. (C) Left ventricular diastolic parameters (E and A waves and E/e0 ratio, n¼ 5 for all groups) and tricuspid annular
plane systolic excursion (TAPSE, n¼ 5 for CO and DOX, n¼ 4 for MYO) assessed by transthoracic echocardiography. We identified significant differences
between the DOX and MYO groups regarding LV diastolic function and RV systolic parameters. *P< 0.05 CO vs. DOX/MYO (ANOVA with Bonferroni
post hoc test).
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fibrosis, and is more strongly upregulated by DOX than by MYO
treatment.
Functional clustering identified the translocator protein (TSPO) as a
central gene in the responsive network (Figure 5), which provides a con-
nection between ISGs (strong expression in MYO) and regulation of
transcription (strong expression in DOX). TSPO is abundantly
expressed in many tissues and organs, including the heart. Among other
functions, it is implicated in apoptosis and cell proliferation and has a pro-
tective role in the myocardium.21 The cardiac expression of TSPO is al-
tered by cellular stress, and it is upregulated in acute stress, but
downregulated after repeated injury. Higher expression in the MYO
group supposedly contributes to mitigation of cardiotoxicity. To further
examine the potential role of TSPO, we stained the protein in LV of
DOX and MYO-treated animals (Figure 6). A typical mitochondrial punc-
tuate pattern and slightly higher intensity of TSPO staining was found in
MYO animals.
Compared to MYO, detection of activated caspase-3 was stronger in
DOX tissue samples (Figure 6). This indicates higher cytotoxicity and
activation of apoptotic pathways caused by higher drug concentrations
in the myocardium. The quantitative western blot showed significantly
higher cleaved caspase 3 activity in LV samples of DOX than in MYO ani-
mals (AUC, DOX vs. MYO: 0.65 ± 0.33 vs. 0.17 ± 0.11 (P< 0.05) (Figure 6).
3.6 Regulation of gene expression related
to collagen production and fibrosis
We also focused on the expression of genes previously associated with
anthracycline toxicity (Supplementary material online, Figure S8). We
detected a strong impact on genes implicated in collagen production and
disposition after anthracycline treatments (Figure 4).22 Among those, a
profound increase of the transcription of collagens and enzymes for col-
lagen maturation, stabilization, and cross-linking was found, including
components of the highly abundant cardiac collagens I and III. COL1A1
and COL1A2 were activated more strongly in the DOX than in the
MYO group, while COL3A1 showed significant induction only in the RV
of MYO. In histological samples, stronger collagen deposition was found
in DOX samples (Figure 6). In addition, genes that are involved in collagen
Figure 4 Heat maps of genes relevant for cardiac function of the left (LV) and right ventricle (RV), and cardiomyopathy in doxorubicin (DOX) and
Myocet (MYO) treated animals. Genes are functionally grouped into indicated clusters. The heat maps illustrate significant upregulation of collagen and re-
lated genes, extracellular matrix and cytoskeleton pathways, genes involved in DNA damage repair, and a less pronounced effect of immune and cell metab-
olism (transforming growth factor/TGF-beta/and mitogen-activated protein kinase/MAPK/) signalling pathways, regulation of growth factors and small
nucleolar RNAs (snoRNA). Significant upregulations are red, downregulations green and non-significant changes grey (all relative to controls, significance for
P< 0.05, moderated t-statistics adjusted for multiple testing).
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.processing and extracellular matrix remodelling were significantly upre-
gulated. These include procollagen peptidase enhancer PCOLCE, the
plasminogen converting enzymes tPA (PLAT) and uPA (PLAU) and its in-
hibitor PAI-1 (SerpinE1), matrix metalloproteinases (MMPs)-2, 11, 14,
and 15, and tissue inhibitors of metalloproteinases (TIMPs)-1 and 3
(Figure 4). Enzymes that catalyze collagen cross-linking (lysyl oxidases
LOXL1-4, lysyl hydroxylases PLOD1 and 3, and transglutaminase
TGM2), folding (proline hydroxylases P4HA1 and 2, and elastin microfi-
bril interlacer Emilin) were also transcriptionally activated. Matricellular
proteins thrombospondin-1 and 2, tenascin-C and X, osteopontin,
osteonectin (SPARC), periostin, and fibronectin are known to be upre-
gulated during reparative cardiac fibrosis.11 However, anthracyclines did
not induce persistent and complete activation of this group of proteins.
However, SPARC was upregulated in all anthracycline groups, and
tenascin-C was upregulated in DOX treated animals. Interestingly, we
found strongly reduced osteopontin (SPP1) expression23 in DOX and
MYO animals in the LV, but not in the RV.
Overall, these data show a strong induction of cardiac fibrosis, both in
the DOX and MYO groups. Collagen 1 and a number of collagen-
regulating genes (SerpinE1 and H1, P4HA1, and PLOD3) were more
strongly induced after DOX treatment.
3.7 Regulation of cellular homeostasis,
inflammation, and signalling pathways
We found deregulation of several genes implicated in response to DNA
damage, and apoptosis (Figure 4). Among those, the heat shock proteins
HSP27 (HSPB1) and HSP60 (HSPD1), which are protective against apo-
ptosis and maintain mitochondrial function, are overexpressed. In con-
trast, kinases ATM and ATR, activated after DNA double strand breaks
and stalled DNA replication, were unchanged or even downregulated.
Their downstream target, the central guardian against genomic muta-
tions, TP53, was slightly upregulated only in MYO. The p53 inhibitor
MDM4 was reduced after anthracycline treatment and several TP53 tar-
gets, such as GADD45B and D, or ERAP1 were upregulated
(Supplementary material online, Figure S9).
We also investigated known signalling pathways of DOX-induced fi-
brosis (Supplementary material online, Figure S10). TGF-b1 was upregu-
lated, while its receptor TGFBR1 showed reduced expression. The
downstream signal transducers SMAD was changed non-significantly, ex-
cept for a downregulation of SMAD5. Neither the MAP-kinase nor the
PI3/Akt pathways were consistently induced in the DOX and MYO
groups.
Transmembrane integrin receptors mediate cellular adhesion to the
ECM and activate distinct signal transduction pathways. Integrins are gen-
erally dysregulated in fibrotic myocardium, with the expression of their
individual subtypes varying in different specific cardiomyopathies.24
Integrins a-1, 3, 5, and 11 and b-1 and 3 are frequently linked to fibrosis
in response to MI, pressure overload, or ageing in animal models. We
found slight upregulation of the a-3 and a-5 subunits in the MYO and
DOX group, respectively, without changes of a-1, a-11, and b-1; b-3
was not detected in the data set. Subunits b-4 and 7 with lesser docu-
mented roles in cardiac fibrosis were found to be upregulated, but in
Figure 5 Protein–protein interactions of differentially expressed genes between MYO and DOX groups in the left (LV) and right ventricle (RV). A cluster
of interferon-responsive genes was strongly upregulated by MYO treatment. Relative to controls, this cluster was upregulated in MYO, but downregulated
in DOX animals. Interferon-inducible genes are upregulated upon DNA damage, and linked with pro-survival and tumour drug resistance. MYO upregulated
several PARP (Poly [ADP-ribose] polymerase) genes, which play an important role in DNA damage repair, and are activated by interferon. Likewise, the mi-
tochondrial translocator protein (TSPO), which has a cardioprotective and inflammation-limiting effect, was significantly repressed by DOX compared to
controls, while its expression was retained after MYO treatment. In addition, DOX showed stronger induction of genes involved in transcriptional and in-
flammatory regulation, apoptosis and stress response. Overall, MYO treatment resulted in activation of pro-survival genes, while DOX induced genes in-
volved in cell death and apoptosis. Considerable overlap of gene expression signatures between LV and RV was found.
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.total no clear and significant transcriptional activation of integrins was
detected. The transmembrane proteoglycan syndecan-1, but not other
syndecans, was upregulated in both LV and RV of treated animals. In
AngII induced fibrosis, syndecan-1 mediates profibrotic signalling through
TGF-b/SMAD signalling.25
Several fibroblast growth factors were upregulated, with the
strongest effect on FGF-9 and 18. We found consistent upregulation
of insulin growth factor binding proteins (IGFBP)-6 and 7, the latter
of which has been linked to heart failure in a clinical study26 and is
regulated by DOX via p53 activation in tumour cell lines.27 IGFBPs
are modulating IGF effects in tissues and may thus serve as a link
between anthracycline induced DNA damage and cardiac fibrosis
and heart failure.
Quantitative PCR of selected genes was performed to verify the NGS
data. All genes showed differential regulation equivalent to the NGS
(Supplementary material online, Figures S11–S18).
Besides genes with well-documented roles in cardiac myopathies and
in DNA damage response (Figure 4), we found dysregulation of a number
of genes with previously undocumented role in the myocardium
(Supplementary material online, Table S4). Several of those are incom-
pletely characterized in Sus scrofa databases and some might be of inter-
est for further investigations. Several small nucleolar RNAs (snoRNAs)
were strongly and uniformly upregulated in both LV and RV of DOX and
MYO animals. snoRNAs are non-coding transcripts that guide nucleotide
modifications of other RNAs. Several members of each the H/ACA box
class, which guides the conversion of uridines to pseudouridines, and the
C/D box class, which guide 20-O-methylations, were affected. Recently,
some snoRNAs have been linked to oxidative stress caused by DOX,28
and the activation in our experiment may represent a new mechanism
for cardiotoxicity.
3.8 Pharmacokinetics
Plasma concentrations upon application of liposomal DOX were 6-
and 14-fold higher than after infusion of the free drug directly after
completion of the first infusion, and 10 min later, respectively (Figure
7A), indicating faster clearance of the free drug compound. Even 2
weeks after the final dose, residual DOX concentrations were
detected in left and right ventricles. As expected, liposomal DOX
resulted in lower myocardial concentrations. These results confirm
the comprehensive pharmacokinetic data collected during pre-clini-
cal and clinical development of Myocet,29,30 and the translational
value of the pig study.
3.9 Concentration-dependent DOX effects
on human cardiomyocytes in vitro
To further investigate the involvement of an interferon response in
DOX cytotoxicity, we treated human cardiomyocytes with increasing
DOX non-lethal concentrations and found a significantly increased
Figure 6 Immunohistochemistry (IHC) and immunofluorescence (IF) analyses of collagen 1, TSPO, and activated caspase-3 with western blot for quantifi-
cation of apoptosis in LV cross sections of pigs treated with either doxorubicin (DOX) or Myocet (MYO). Representative pictures show stronger interstitial
collagen deposition after DOX treatment. Blue, DAPI staining of nuclei; red, actin stained by phalloidin; green, respective protein stained by antibody.
Intracellular localization of TSPO is similar in both groups, with a distinct punctuate pattern indicative for mitochondrial localization, with higher signal inten-
sity in MYO group (green). Bottom row: Representative image of western blot of cleaved caspase-3 and tubulin as loading control, with significantly higher
caspase-3 activity in DOX as compared to MYO samples. *P< 0.0. Scale bars: 50mm (IHC), 100mm (IF), and 20mm (caspase-3).
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..expression of DHX58 and OAS1 after applying low DOX concentra-
tions (Figure 7B). This confirms a concentration-dependent effect on
interferon-responsive genes. We next examined whether an interferon
response has a direct effect on DOX cytotoxicity on cardiomyocytes.
Pre-treatment of cardiomyocytes with the nucleic acid and Toll-like re-
ceptor ligand poly (I:C)31 strongly induced expression of the selected set
of interferon-responsive genes (Figure 7C), and induced a significant
protection against DOX cytotoxicity as assessed by mitochondrial
activity (Figure 7D) in a short incubation time (48 h) by using a single
dose. A second assay directly compared the myocardial cell viability
after 24 h of incubation with either DOX or MYO in equivalent
concentrations, which showed a similar IC50 but diverging toxicity at
higher doses. Significantly preserved cell viability was observed from
1 nM drug concentration in the MYO-treated cell culture, compared to
DOX (P< 0.01; Figure 7E) with similar cell viability curves of the poly
(I:C)-stimulated and MYO-treated cells. Taken together, the lower myo-
cardial DOX level by applying MYO and the stronger expression of
interferon-responsive genes by a lower tissue drug concentration, the
in vitro experiment indirectly proves the role of interferon-associated
mitigation of cardiotoxicity by MYO.
4. Discussion
In line with the clinical knowledge,32 liposomal encapsulation of DOX
(MyocetVR ) reduced heart damage compared to the free drug in pigs, evi-
denced by body weight and LV and RV functional parameters.
Liposomes exhibit a distinctly altered biodistribution pattern than the li-
pophilic small molecule DOX: organ distribution is predominantly influ-
enced by their large size, which reduces accumulation in organs with
tight endothelium such as the heart, but increases extravasation into tis-
sues with leaky or fenestrated vessels, such as tumour tissue.33 In clinical
trials, liposomal DOX had a more than five-fold lower clearance and an
approximately 10- to 15-fold lower volume of distribution (Vss), indica-
tive of the lower degree of tissue uptake.30,34 In dogs, peak and overall
drug concentrations in the myocardium was 30–40% lower after liposo-
mal DOX application compared to the free compound.35 Our analyses
of drug concentrations in plasma and heart tissue confirmed these data
also for pigs. Both for DOX and its liposomal formulations, the cardio-
toxicity is dependent upon the cumulative administered dose36 and the
better therapeutic index of liposomal formulations are attributed to a
lower heart accumulation while maintaining anti-tumour efficacy.37
Figure 7 Doxorubicin pharmacokinetics and in vitro effects on interferon-responsive genes and cell viability. (A) Doxorubicin concentrations in plasma
and heart tissue of pigs were analysed by UPLC-MS after application as free drug (DOX) or as liposomal formulation (MYO). Ten minutes after the end of
the 1-h infusion, higher drug concentrations were found after treatment with MYO, which were subsequently reduced more slowly than after application of
the free drug (DOX), indicative of lower clearance, and slower distribution to cardiac tissues. Two weeks after the third and final treatment cycle, the drug
concentration in myocardial samples was still lower after application of MYO compared to DOX. (B) Human cardiomyocytes were treated in vitro with
doxorubicin in sublethal concentrations, and the effect on expression of selected interferon-inducible genes, which were upregulated in porcine hearts
in vivo by MYO, but not DOX, was assessed. Expression of DHX58 and OAS1 was induced by 1.56 nM DOX, but not by higher concentrations. (C)
Induction of an interferon response by treating human cardiomyocytes with poly (I:C), a ligand of Toll-like receptor 3. Strong increase of expression was ob-
served for the selected interferon-responsive genes. (D) Significantly increase in viability of human cardiomyocytes after induction of interferon response by
poly (I:C) and doxorubicin. (E) In vitro comparison of 24 h incubation of DOX vs. MYO cytotoxicity. Cell viability diverged at higher concentrations with a sig-
nificant difference from 1mM indicating an overall lower cytotoxic effect at higher drug concentrations.*P< 0.05.
Interferon response in anthracycline cardiotoxicity 11
D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvz192/5538977 by U
niversitaetsbibliothek Bern user on 16 August 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
These alterations in tissue accumulation and in particular the lower Cmax
in the myocardium are responsible for the overall lower toxicity of lipo-
somal DOX in pigs. The encountered expressional alterations may serve
as a basis for devising novel cardioprotective strategies against anthracy-
cline toxicity.
The most pronounced difference in the RNA-sequencing analysis is
the induction and repression of ISGs by MYO, and DOX, respectively
(Figure 5). Although best known as a key component of the innate im-
mune response and an antiviral defense mechanism, interferon-inducible
genes are being increasingly recognized for mediating cell survival after
cytostatic stimuli, including irradiation and anthracycline therapy.38 It has
been shown that anthracyclines activate the innate immune response in
concentrations well below cytostatic levels.39 Higher expression of a set
of genes termed interferon-related DNA damage signature is connected
with DNA damage resistance after DOX treatment.40 Together with
stronger induction of stress response genes by DOX, we propose a
mechanism for mitigation of cardiotoxicity by liposomal encapsulation.
The limited peak concentration in the heart results in less severe DNA
damage and ROS activation, and consequently, an upregulation of ISGs.
Activation of this subset of ISGs, as seen after liposomal DOX treatment,
induces a pro-survival cell response. On the other hand, the more pro-
found damage caused by higher cardiac DOX concentrations (after
unpackaged application) fails to induce ISGs and drives the cell towards
cell death. This is reflected by a more severe impact on expression of
collagens and ECM genes as indications of cardiac fibrosis, as well as clini-
cal outcomes. The TSPO is potentially central in linking DNA damage,
ROS production, interferon response, and finally fibrosis genes. Because
of its complex roles in the innate immune system, the interferon re-
sponse appears to be difficult to exploit for adjuvant therapy. In contrast,
TSPO might be a viable target. TSPO ligands are cardioprotective and
limit ischaemia–reperfusion damage.21 In isolated cardiomyocytes, the
TSPO ligands 40-chlorodiazepam and TRO40303 reduced DOX-in-
duced dysfunction and cell death.41
Pharmacokinetic analyses confirmed a lower myocardial concentra-
tion of the cytotoxic drug when applied in its liposomal form. This is
reflected by lower expression of the apoptosis marker activated
caspase-3 in MYO animals (Figure 7). In vitro experiments on isolated hu-
man cardiomyocytes confirmed a concentration-dependent effect on
gene expression in sublethal DOX concentrations, with lower concen-
tration activating interferon-inducible genes. Stimulation of interferon
through TLR-3 protected cardiomyocytes against acute DOX cytotoxic-
ity. Myocardial cell viability was significantly more preserved after incuba-
tion of the cells with MYO, as compared to DOX, thus the in vitro data
corroborate the results of the in vivo study. However, several factors, in-
cluding involvement of fibroblasts and other cell types, the varying extent
and mechanisms of ISG-stimulation, and exposure times to drug levels
with subclinical toxicity need to be considered for comparing in vitro and
in vivo models. Importantly, there is no reliable method for detection of
chronic toxicity caused by repetitive drug administration in simplified
in vitro models. Meaningful in vivo models with high translational value are
essential for adequate assessment of molecular mechanisms of
cardiotoxicity.
4.1 Relevant pre-clinical signs of cardiotox-
icity and cardiac fibrosis
Of note, treatment of pigs with doses equivalent to human application
resulted in significant cardiovascular toxicity in all groups. This finding is
in contrast with the generally accepted view that cardiotoxicity is a rare
to moderately frequent complication of DOX treatment with an inci-
dence of heart failure between 5% and 48% depending on the cumulative
dose.5,42 In our experiment, the cumulative dose failed to reach this limit,
yet all animals experienced elevated TnI, even when signs of clinical heart
failure (e.g. congestion, dyspnoea) were absent. Moreover, the animals
were healthy at the time of the study start, and lacking conventional risk
factors. Their young age suggests increased sensitivity to adverse effects
of chemotherapy.
In conclusion, we show a uniform and pronounced upregulation of
collagens and genes associated with tissue fibrosis in both LV and RV,
and both DOX and MYO groups. Together with impaired cardiac
function, these data clearly show that cardiac fibrosis was induced by
anthracyclines at an early stage. Although the extent of upregulation of
fibrosis-associated genes was lower after Myocet, similar caution and in
particular close observation of cardiac function is advisable. Our data
suggest that primary prevention of cardiotoxicity may be the right choice
for all patients before starting anticancer therapy.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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Translational perspective
Although treatment of pigs with doxorubicine, epirubicine, and liposomal encapsulation of doxorubicin (Myocet) with doses equivalents to human
application resulted in mild to severe cardiovascular toxicity in all animals, Myocet reduced the cardiac damage evidenced by better left and right ven-
tricular functional parameters measured by cardiac MRI, and less myocardial apoptosis and fibrosis. Pharmacokinetics resulted in lower myocardial
concentration of the chemotherapeutic drug after administration of Myocet, compared to doxorubicine. Deep sequencing analysis revealed activated
interferon-responsive genes associated with pro-survival signals by Myocet both in right and left ventricular myocardium, which explain the reduced
cardiotoxicity on a molecular level.
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